Healthcare Industry News:  King Pharmaceuticals 

Biopharmaceuticals Personnel

 News Release - December 4, 2006

King Pharmaceuticals Board Names Brian Markison to Succeed Ted Wood as Chairman

Wood to Become Lead Director

BRISTOL, Tenn.--(HSMN NewsFeed)--King Pharmaceuticals (NYSE: KG ) announced today that its board of directors has appointed Brian A. Markison to succeed Ted G. Wood as the chairman of the company's board. The appointment will be effective at the close of the company's May 2007 annual meeting of shareholders. Mr. Wood will remain a member of King's board and will serve as lead independent director. Mr. Markison will continue as King's president and chief executive officer.

Mr. Wood stated, "Since his appointment as CEO in May 2004, Brian has demonstrated exceptional leadership and financially rebased our company. Additionally, he has been instrumental in establishing and executing our strategic focus, utilizing the talents of the exemplary management team he has assembled. The entire board shares my confidence in Brian's ability to lead our company as we continue to successfully execute our strategy for long-term growth. Accordingly, I believe that Brian's appointment as Chairman of King's board of directors is both timely and appropriate."

Mr. Markison said, "On behalf of all King shareholders and employees, I want to thank Ted for his commitment and for the invaluable guidance he has provided as King's chairman for over two years. Ted's contributions to King's development have been significant and we are pleased that he will continue to serve on the board as lead independent director following the 2007 annual meeting. This is an exciting time for King as we continue to focus on driving growth and creating shareholder value and it will be an honor for me to serve as chairman."

About King Pharmaceuticals

King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products in attractive markets and the strategic acquisition of branded products that can benefit from focused promotion and marketing and product life-cycle management.


Source: King Pharmaceuticals

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.